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CONCLUSION: Average medical costs of treatment
were the highest for patients with no recorded comorbid-
ity in 1995. In contrast, the median cost estimates were
the lowest for these patients. Results indicated that distri-
butions of medical costs were positively skewed; the ob-
servation was most prominent in the population with no
recorded comorbidities associated with type-2 diabetes
mellitus. This finding may result from several factors in-
cluding coding, severity, and/or compliance.
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Diabetes is a chronic illness with type 2 diabetes repre-
senting 80% of all diagnosed diabetes. In recent years, a
number of instruments have been developed to measure
the HRQOL of patients with type 2 diabetes. Good psy-
chometric properties of these instruments are important
for their use in studies evaluating the effect of interven-
tions to increase metabolic control. OBJECTIVE: To re-
view the QOL literature with focus on HRQOL measure-
ments in type 2 diabetes. METHOD: We identified HRQOL
instruments for type 2 diabetes using MEDLINE (En-
glish), and reviewed the resulting publications for evi-
dence of reliability, validity, and responsiveness. RE-
SULTS: Several English-language generic and disease-
specific measures were identified. These instruments have
been used both in mixed diabetes populations and in
solely type 2 patients, including insulin users. The instru-
ments in the studies reviewed have acceptable reliability
and validity in tested populations. Few of these HRQOL
measures have been tested for sensitivity to changes in
metabolic control through pharmacological or non-phar-
macological interventions. One recently published drug
study provided support for the responsiveness of scales in
an unpublished HRQOL instrument. CONCLUSIONS:
Generic instruments such as the MOS SF-36 and EQ5D
may or may not be sensitive to change in HRQOL related
to diabetes and its treatment. Disease-specific instru-
ments have shown more sensitivity, but may fail to cap-
ture all relevant domains and do not apply to the specific
diabetes population under investigation. The responsive-
ness of instruments has not been addressed adequately in
the studies. More studies are needed to further assess reli-
Table 2. Medical costs ($)
Populations
Total
Diabetes and 
associated 
comorbidities
Average Median Average Median
Nhtn 1,964 471 427 184
Nhlpd 1,197 571 374 225
Nnoco 2,735 456 594 166
ability, validity and most importantly, responsiveness of
the existing instruments.
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OBJECTIVE: To develop a method to test the hypothesis
that DM and HT are the most frequent concomitant ill-
nesses among such disease groups as cardiovascular
(CVD), joint disorders, renal failure, liver and kidney dis-
eases and to calculate the annual medical care costs of
HT and DM compared with estimated average care costs
in the disease groups. METHODS: Diagnosis-specific es-
timates for health care utilization and associated medical
expenses were constructed by employing a linear model
with exogenous population weights and normalizing co-
efficients using the National Medical Expenditure Survey
data. Statistical analyses for demographic parameters and
design effects on mean cost were obtained using linear re-
gression models. RESULTS: Among diabetics the most
prevalent conditions were HT (40%), CVD (26%), joint
disorders (23%), and fatigue (21%). DM and any of the
15 comorbidities incurred annual average costs ranging
from $2000 to $48,100, 1.5 to 3.5-fold higher than the
estimated disease-specific average costs. Among patients
with HT the most prevalent conditions were joint disor-
ders (23%), CVD (22%), fatigue (20%), and DM (18%).
HT and any of the 15 comorbidities incurred annual av-
erage medical costs 1.3–2.5-fold higher than the esti-
mated disease-specific average medical costs. Patients
with DM and HT constitute over 60% of all patients
treated annually for CVD, 52% for renal failure, 55%
for joint disorders and 45% with liver diseases. Federal
programs compensate 38% of medical care costs in HT
and 56% in DM. Out-of-pocket expenses pay 37% of
costs in HT and 20% in DM. CONCLUSION: Our find-
ings suggest that HT and DM are responsible for more
than 60% of health care costs in some of the 15 re-
searched disease categories. Treating of DM and HT to
goal will help to contain medical care costs for health
care providers and payers irrespective of any other co-
morbidity, and contribute to cost-effective disease man-
agement, and quality of care.
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